#Novo Nordisk
Total 7 articles
Danish pharma giant Novo Nordisk saw $50 billion wiped off its market value as competition threatens its dominance in the lucrative obesity drug market.
The China obesity drug price war 2026 is heating up as companies slash prices by 80%. Discover how Novo Nordisk and Eli Lilly are responding to local competition.
Amazon Pharmacy now offers Novo Nordisk’s oral Wegovy pill starting at $149 for cash-paying patients. Discover how this impacts the healthcare market.
PRISM by Liabooks
Place your ad in this space
[email protected]
Discover the future of GLP-1 weight-loss pills in 2026. From oral medication to TikTok influencers and telehealth apps, see how the market is changing.
Novo Nordisk (NVO) stock jumped 8% following FDA approval for the oral pill version of its weight-loss drug Wegovy. The move is expected to significantly broaden patient access and intensify competition with Eli Lilly.
The US FDA has approved the first-ever pill form of Novo Nordisk's blockbuster weight-loss drug, Wegovy. Showing comparable results to the injection in trials, the daily pill is set to launch in January 2026.
The FDA has approved a once-daily pill version of Novo Nordisk's blockbuster weight-loss drug Wegovy, offering a new option versus the weekly shot and escalating competition with Eli Lilly.
PRISM by Liabooks
Place your ad in this space
[email protected]